Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL.

被引：0
|
作者：
Wierda, WG [1 ]
OBrien, S [1 ]
Ferrajoli, A [1 ]
Faderl, S [1 ]
Koller, C [1 ]
Giles, F [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Ravandi, F [1 ]
Garcia-Manero, G [1 ]
Andreeff, M [1 ]
Lerner, S [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
719
引用
收藏
页码：213A / 213A
页数：1
相关论文
共 48 条
  • [31] A comparison of acute and delayed infection rates among patients with indolent lymphoid malignancies receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).
    Tam, CS
    Seymour, JF
    Brown, M
    Campbell, P
    Scarlett, JD
    Underhill, C
    Ritchie, D
    Bond, R
    Grigg, A
    BLOOD, 2004, 104 (11) : 905A - 905A
  • [32] Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients
    Khanna, N
    Klimkait, T
    Schiffer, V
    Irigoyen, J
    Telenti, A
    Hirschel, B
    Battegay, M
    AIDS, 2000, 14 (07) : 791 - 799
  • [33] Bendamustine is a safe and effective therapy in heavily pre-treated patients with B-cell-chronic lymphocytic leukaemia (B-CLL), even with pre-existing autoimmune phenomena.
    Schulte, K
    Aivado, M
    Neise, M
    Strupp, C
    Losem, C
    Hentze, L
    Haas, R
    BLOOD, 2001, 98 (11) : 292B - 292B
  • [34] Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Trial, International, Randomized Study Of The German CLL Study Group (GCLLSG)
    Eichhorst, Barbara
    Fink, Anna-Maria
    Busch, Raymonde
    Lange, Elisabeth
    Koeppler, Hubert
    Kiehl, Michael
    Soekler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Koechling, Georg
    Ploeger, Christoph
    Gregor, Michael
    Plesner, Torben
    Trneny, Marek
    Fischer, Kirsten
    Doehner, Hartmut
    Kneba, Michael
    Wendtner, Clemens
    Klapper, Wolfram
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Hallek, Michael
    BLOOD, 2013, 122 (21)
  • [35] Seventy percent of complete responders remain in continuous remission: Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL
    Tam, C. S.
    O'Brien, S.
    Wierda, W.
    Lerner, S.
    Kantarjian, H.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and ritux-imab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL).
    Keating, MJ
    O'Brien, S
    Lerner, S
    Wierda, W
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 573S - 573S
  • [37] Rituximab (R) in combination with fludarabine (F) and cyclophosphamide (C) in relapsed follicular lymphoma (FL) patients (pts). Final results of FC plus R phase II trial by the GISL.
    Sacchi, Stefano
    Pozzi, Samantha
    Marcheselli, Raffaella
    Luminari, Stefano
    Federico, Massimo
    Tucci, Alessandra
    Merli, Francesco
    Orsucci, Loretta
    Cervetti, Giulia
    Occhini, Ubaldo
    Liberati, Marina
    Callea, Vincenzo
    Brugiatelli, Maura
    Baldini, Luca
    BLOOD, 2006, 108 (11) : 782A - 782A
  • [38] Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara
    Fink, Anna Maria
    Busch, Raymonde
    Kovacs, Gabor
    Maurer, Christian
    Lange, Elisabeth
    Koeppler, Hubert
    Kiehl, Michael G.
    Soekler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Koechling, Georg R. A.
    Ploeger, Christoph
    Gregor, Michael
    Plesner, Torben
    Trneny, Marek
    Fischer, Kirsten
    Doehner, Hartmut
    Kneba, Michael
    Wendtner, Clemens-Martin
    Klapper, Wolfram
    Kreuzer, Karl Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Hallek, Michael
    BLOOD, 2014, 124 (21)
  • [39] Safety and Efficacy Of Abbreviated Induction With Only 4 Cycles Of Fludarabine (F), Cyclophosphamide (C) and Rituximab (R) In Physically Fit Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Early Complete Remission (CR) With Undetectable Minimal Residual Disease (MDR)
    Pavlovsky, Carolina
    Pavlovsky, Astrid
    Fernandez, Isolda
    Galeano, Adriana
    Lastiri, Francisco
    Pavlovsky, Santiago
    BLOOD, 2013, 122 (21)
  • [40] Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients (vol 14, pg 791, 2000)
    Khanna, N
    Klimkait, T
    Schiffer, V
    Irigoyen, J
    Telenti, A
    Hirschel, B
    Battegay, M
    AIDS, 2000, 14 (09) : 1297 - 1297
12345